| Expression pattern: |
UP |
| Associated gene: |
14-3-3zeta, YAP, p-LATS1/2, CTGF, CYR61, TEAD1-4 |
| Associated microRNA: |
- |
| Biological function: |
promotes HCC cell proliferation, migration, invasion, metastasis and angiogenesis; inhibits apoptosis; promotes tumor growth and lung metastasis in vivo; induces lenvatinib resistance and can transmit resistance via exosomes |
| Molecular mechanism: |
binds 14-3-3zeta competitively with YAP, weakening 14-3-3zeta-mediated recruitment/cytoplasmic fixation of YAP and reducing YAP phosphorylation by p-LATS, thereby promoting YAP nuclear localization and inactivating the Hippo signaling pathway; exosomal transfer of circPAK1 confers lenvatinib resistance |
| Biological pathway or process: |
Hippo/YAP (inhibits); proliferation (promotes); migration (promotes); invasion (promotes); metastasis (promotes); angiogenesis (promotes); apoptosis (inhibits); drug resistance (promotes) |
| Detected method: |
Q
S
|
| Validation methods: |
circRNA-seq; RT-qPCR; Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; Actinomycin D / DRB Stability Assay; FISH / smFISH; Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; RNA-seq; RNA Pull-Down; RIP (RNA Immunoprecipitation); Co-IP; Western Blot; IF (Immunofluorescence); Transfection; CCK8; EdU Staining; Colony Formation Assay; Transwell Assay; Wound Healing Assay; Annexin V/PI Flow Cytometry; Tube Formation Assay; In Vivo Animal Model; H&E Staining; IHC (Immunohistochemistry); Bioinformatics Analysis; Survival Analysis |
| Clinical significance: |
high expression of circPAK1 negatively correlated with OS and DFS and was associated with aggressive clinicopathological features |
| Description: |
circPAK1 is upregulated in HCC tissues/cell lines and promotes proliferation, migration/invasion, metastasis and angiogenesis while inhibiting apoptosis. It binds 14-3-3zeta competitively with YAP, promoting YAP nuclear localization and Hippo pathway inactivation. circPAK1 is enriched in exosomes from lenvatinib-resistant cells and can transfer resistance to recipient HCC cells. |
| Confidence score: |
0.8949 |